Kite Pharma (KITE) late Monday reported positive clinical data from a treatment with patients with aggressive Non-Hodgkin lymphoma, with shares sharply higher Tuesday morning.
Meanwhile, RV maker Thor Industries (THO) reported better-than-expected fiscal fourth-quarter earnings.
Kite Pharma announced positive top-line results from an interim analysis of its leading candidate KTE-C19, in patients with chemorefractory diffuse large B-cell lymphoma. Kite reported 47% had complete remission, with 76% showing some positive response. But many patients did suffer severe side effects, as expected.
Kite Pharma shares jumped 9% to to 59.91 in morning trade on the stock market today. Peers in the chimerica antigen receptor T-cell (CAR-T) field rose in sympathy. Juno Therapeutics (JUNO) climbed 6.9% to 31.69.
RELATED:
Juno Therapeutics Stock Up On Latest CAR-T Data
Thor Industries
Estimates: Thor Industries was expected to report a 17% earnings per share gain to $1.33 a share, with sales rising 19.5% to $1.058 billion.
Prior Quarter: Thor EPS rose 27% to $1.51 as sales climbed 9% to $1.284 billion.
Results: Thor earned $1.57 a share, up 20%, with sales climbing 22% to $1.29 billion. That's the best sales gain in six quarters.
Shares: Thor rose 3.35% to 85.51, eclipsing its Sept. 7 all-time high of 83.62.
IBD'S TAKE: Recreational vehicles can cost up to half a million dollars. With gas prices low and baby boomers ready to spend their children's inheritance, here's an in-depth look into booming RV demand and RV stocks.
Among related companies, Winnebago (WGO) shares rose 1.2% Tuesday morning. Drew Industries (DW) fell 0.6%. Drew, which makes parts for RVs and mobile homes, has been finding support at the 50-day line in recent sessions.
RELATED:
Amid Big Market Sell-Off, Which IBD 50 Names Continue To Show Mettle?
